Chemical Compound Review:
AC1L3VEW (2S)-2-[5,6-dichloro-2- (propan-2...
Synonyms:
- Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. Chou, S., Marousek, G.I., Senters, A.E., Davis, M.G., Biron, K.K. J. Virol. (2004)
- Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. Zacny, V.L., Gershburg, E., Davis, M.G., Biron, K.K., Pagano, J.S. J. Virol. (1999)
- The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. Krosky, P.M., Baek, M.C., Coen, D.M. J. Virol. (2003)
- Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Lalezari, J.P., Aberg, J.A., Wang, L.H., Wire, M.B., Miner, R., Snowden, W., Talarico, C.L., Shaw, S., Jacobson, M.A., Drew, W.L. Antimicrob. Agents Chemother. (2002)
- Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Koszalka, G.W., Johnson, N.W., Good, S.S., Boyd, L., Chamberlain, S.C., Townsend, L.B., Drach, J.C., Biron, K.K. Antimicrob. Agents Chemother. (2002)
- Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position. Baek, M.C., Krosky, P.M., He, Z., Coen, D.M. J. Biol. Chem. (2002)
- Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. Prichard, M.N., Britt, W.J., Daily, S.L., Hartline, C.B., Kern, E.R. J. Virol. (2005)
- Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. Komazin, G., Ptak, R.G., Emmer, B.T., Townsend, L.B., Drach, J.C. J. Virol. (2003)
- Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Chou, S., Marousek, G.I. Antimicrob. Agents Chemother. (2006)
- Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. Drew, W.L., Miner, R.C., Marousek, G.I., Chou, S. J. Clin. Virol. (2006)
- Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults. Ma, J.D., Nafziger, A.N., Villano, S.A., Gaedigk, A., Bertino, J.S. Antimicrob. Agents Chemother. (2006)
- Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Chou, S., Van Wechel, L.C., Marousek, G.I. Antimicrob. Agents Chemother. (2006)
- Maribavir (ViroPharma). Lu, H., Thomas, S. Current opinion in investigational drugs (London, England : 2000) (2004)
- N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole. Lorenzi, P.L., Landowski, C.P., Brancale, A., Song, X., Townsend, L.B., Drach, J.C., Amidon, G.L. Drug Metab. Dispos. (2006)
- Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Evers, D.L., Komazin, G., Shin, D., Hwang, D.D., Townsend, L.B., Drach, J.C. Antiviral Res. (2002)
- Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Kern, E.R. Antiviral Res. (2006)
- Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. Gershburg, E., Hong, K., Pagano, J.S. Antimicrob. Agents Chemother. (2004)
- Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. Gershburg, E., Pagano, J.S. J. Virol. (2002)
- The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. Krosky, P.M., Baek, M.C., Jahng, W.J., Barrera, I., Harvey, R.J., Biron, K.K., Coen, D.M., Sethna, P.B. J. Virol. (2003)
- Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Wang, L.H., Peck, R.W., Yin, Y., Allanson, J., Wiggs, R., Wire, M.B. Antimicrob. Agents Chemother. (2003)
- Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Chulay, J., Biron, K., Wang, L., Underwood, M., Chamberlain, S., Frick, L., Good, S., Davis, M., Harvey, R., Townsend, L., Drach, J., Koszalka, G. Adv. Exp. Med. Biol. (1999)